Published in Proc Natl Acad Sci U S A on March 30, 1999
Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J Biol Chem (2006) 1.25
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc Natl Acad Sci U S A (2001) 1.14
Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci U S A (2002) 1.11
Programmed cell death in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.04
HSV Recombinant Vectors for Gene Therapy. Open Virol J (2010) 0.99
Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol (2000) 0.98
Future of cell and gene therapies for Parkinson's disease. Ann Neurol (2008) 0.92
HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia (1999) 0.88
Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J Virol (2004) 0.83
Herpes simplex virus-based vectors. Int J Exp Pathol (2004) 0.80
Protection of Tong-Sai-Mai Decoction against Apoptosis Induced by H2O2 in PC12 Cells: Mechanisms via Bcl-2-Mitochondria-ROS-INOS Pathway. Evid Based Complement Alternat Med (2014) 0.76
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells. Biologics (2009) 0.76
Investigation of the therapeutic potential of N-acetyl cysteine and the tools used to define nigrostriatal degeneration in vivo. Toxicol Appl Pharmacol (2016) 0.75
Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability. J Neural Transm (Vienna) (2007) 0.75
Gene therapy targeting mitochondrial pathway in Parkinson's disease. J Neural Transm (Vienna) (2016) 0.75
The Bcl-2 protein family: arbiters of cell survival. Science (1998) 16.08
Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell (1993) 10.83
Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol (1985) 8.12
The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med (1997) 6.41
Double identity for proteins of the Bcl-2 family. Nature (1997) 5.60
Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res (1970) 4.65
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol (1968) 2.81
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci (1985) 2.70
Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci U S A (1996) 2.50
Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience (1994) 2.40
Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science (1997) 2.40
Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol (1998) 2.20
Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science (1984) 1.72
Neural apoptosis. Ann Neurol (1995) 1.49
Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci (1996) 1.42
Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci (1996) 1.35
Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. J Neurochem (1996) 1.29
Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol (1997) 1.28
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A (1997) 1.26
Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci U S A (1995) 1.26
Energy metabolism during apoptosis. Bcl-2 promotes survival in hematopoietic cells induced to apoptose by growth factor withdrawal by stabilizing a form of metabolic arrest. J Biol Chem (1997) 1.25
Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A (1997) 1.14
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci (1998) 1.14
Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A (1996) 1.12
6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration (1995) 1.11
Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol (1997) 1.11
Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci U S A (1998) 1.11
Expression of bcl-2 inhibits necrotic neural cell death. J Neurosci Res (1995) 1.08
Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience (1994) 1.03
Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2. Synapse (1997) 1.02
Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest (1995) 1.02
Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra. J Neurosci (1997) 0.98
Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull (1991) 0.91
Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells. J Neurochem (1998) 0.87
p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res (1997) 0.85
Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2. Cell Mol Neurobiol (1997) 0.85
Engineering herpes simplex virus vectors for gene transfer to neurons. Nat Med (1997) 0.85
Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord (1997) 0.82
Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen. Brain Res Bull (1991) 0.81
Cloning of herpes simplex virus type 1 sequences representing the whole genome. J Virol (1981) 5.66
Transcriptional and genetic analyses of the herpes simplex virus type 1 genome: coordinates 0.29 to 0.45. J Virol (1984) 4.09
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 4.02
Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration. J Virol (1987) 3.74
CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med (2000) 3.62
Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem (1994) 3.14
High-frequency transfer of cloned herpes simplex virus type 1 sequences to mammalian cells by protoplast fusion. Mol Cell Biol (1981) 2.97
Physical mapping of the mutation in an antigenic variant of herpes simplex virus type 1 by use of an immunoreactive plaque assay. J Virol (1983) 2.96
Mutations in herpes simplex virus type 1 genes encoding VP5 and VP23 abrogate capsid formation and cleavage of replicated DNA. J Virol (1993) 2.79
Transcriptional control signals of a herpes simplex virus type 1 late (gamma 2) gene lie within bases -34 to +124 relative to the 5' terminus of the mRNA. Mol Cell Biol (1986) 2.65
The pseudorabies virus gII gene is closely related to the gB glycoprotein gene of herpes simplex virus. J Virol (1987) 2.58
Rapid identification of nonessential genes of herpes simplex virus type 1 by Tn5 mutagenesis. Science (1987) 2.57
Species and type phages of lactococcal bacteriophages. Intervirology (1991) 2.55
Genome comparison of Lactococcus strains by pulsed-field gel electrophoresis. FEMS Microbiol Lett (1989) 2.36
Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res (1998) 2.35
Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science (1979) 2.22
Expression of herpes simplex virus beta and gamma genes integrated in mammalian cells and their induction by an alpha gene product. Mol Cell Biol (1983) 2.15
A specific 15-bp TATA box promoter element is required for expression of a herpes simplex virus type 1 late gene. Genes Dev (1988) 2.11
Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration. J Virol (1988) 1.94
Immune interactions with cells infected with herpes simplex virus: antibodies to radioiodinated surface antigens. J Immunol (1977) 1.94
Possible role of Fc receptors on cells infected and transformed by herpesvirus: escape from immune cytolysis. Infect Immun (1978) 1.93
Method for induction of mutations in physically defined regions of the herpes simplex virus genome. J Virol (1981) 1.89
A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol (1994) 1.86
Inversion events in the HSV-1 genome are directly mediated by the viral DNA replication machinery and lack sequence specificity. Cell (1988) 1.84
Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants. J Virol (1988) 1.74
Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem (1980) 1.73
Innovative materials processing strategies: a biomimetic approach. Science (1992) 1.72
Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A (1999) 1.68
Regulation of the herpes simplex virus type 1 late (gamma 2) glycoprotein C gene: sequences between base pairs -34 to +29 control transient expression and responsiveness to transactivation by the products of the immediate early (alpha) 4 and 0 genes. Nucleic Acids Res (1987) 1.68
Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A (1993) 1.65
HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther (2005) 1.63
Syncytium-inducing mutations localize to two discrete regions within the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B. J Virol (1993) 1.63
Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem (1999) 1.62
Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites. J Virol (1985) 1.60
Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia (2002) 1.55
Identification of mar mutations in herpes simplex virus type 1 glycoprotein B which alter antigenic structure and function in virus penetration. J Virol (1989) 1.52
Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J Virol (1994) 1.51
Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Virology (1990) 1.49
Mutant analysis of herpes simplex virus-induced cell surface antigens: resistance to complement-mediated immune cytolysis. J Virol (1980) 1.48
Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity. J Virol (1985) 1.45
PCR-based analysis of herpes simplex virus type 1 latency in the rat trigeminal ganglion established with a ribonucleotide reductase-deficient mutant. J Virol (1994) 1.45
Physical and genetic map of the chromosome of Lactococcus lactis subsp. lactis IL1403. J Bacteriol (1992) 1.43
An X Window system for statlab results reporting. Proc Annu Symp Comput Appl Med Care (1993) 1.43
HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther (2005) 1.42
Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther (2001) 1.41
Some thoughts on the nature of ectopic parathyroid hormones. Am J Med (1971) 1.39
Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production. J Virol (1986) 1.39
Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol (1992) 1.37
Effect of cross-immunization on monotypic antibody responses to herpes simplex virus types 1 and 2. J Immunol (1976) 1.37
Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections. J Virol (1995) 1.37
Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther (2007) 1.37
Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther (1998) 1.36
Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci (1996) 1.35
Localization of a functional site on herpes simplex virus type 1 glycoprotein C involved in binding to cell surface heparan sulphate. J Gen Virol (1994) 1.35
Molecular basis of the glycoprotein C-negative phenotypes of herpes simplex virus type 1 mutants selected with a virus-neutralizing monoclonal antibody. J Virol (1986) 1.33
New tools for the physical and genetic mapping of Lactococcus strains. Gene (1992) 1.31
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther (1996) 1.31
A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J Virol (1992) 1.29
Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol (2001) 1.27
Relationship between expression of herpes simplex virus glycoproteins and susceptibility of target cells to human natural killer activity. J Exp Med (1983) 1.27
Localization on the herpes simplex virus type 1 genome of a region encoding proteins involved in adsorption to the cellular receptor. J Virol (1990) 1.26
In vivo metabolism of complement. I. Metabolism of the third component (C'3) in acquired hemolytic anemia. J Clin Invest (1969) 1.26
The mixed lineage kinase DLK utilizes MKK7 and not MKK4 as substrate. J Biol Chem (1999) 1.26
Microbiological studies on septicemic bullfrogs (Rana catesbeiana). Am J Vet Res (1974) 1.26
Persistence of herpes simplex virus genes in cells of neuronal origin. J Virol (1980) 1.25
Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol (1999) 1.24
Infection by herpes simplex virus and cells of nervous system origin: characterization of a non-permissive interaction. J Gen Virol (1978) 1.24
Gene delivery to cartilage defects using coagulated bone marrow aspirate. Gene Ther (2004) 1.24
Taxonomic differentiation of 101 lactococcal bacteriophages and characterization of bacteriophages with unusually large genomes. Appl Environ Microbiol (1990) 1.24
Adhesion of type A Pasteurella mulocida to rabbit pharyngeal cells and its possible role in rabbit respiratory tract infections. Infect Immun (1982) 1.23
HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther (2007) 1.22
Biomineralization and eggshells: cell-mediated acellular compartments of mineralized extracellular matrix. Int Rev Cytol (1993) 1.22
The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection. J Virol (1993) 1.22
Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol (1995) 1.22
Complement-mediated cytolysis of HSV-1 and HSV-2 infected cells: plasma membrane antigens reactive with type-specific and cross-reactive antibody. J Gen Virol (1978) 1.21
Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. J Virol (2000) 1.20
Regulation of acetylcholine release from neuroblastoma x glioma hybrid cells. Proc Natl Acad Sci U S A (1978) 1.19
Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J Infect Dis (1991) 1.18
Specificity of human natural killer cells in limiting dilution culture for determinants of herpes simplex virus type 1 glycoproteins. J Virol (1986) 1.16
Molecular characterization and comparison of 38 virulent and temperate bacteriophages of Streptococcus lactis. J Gen Microbiol (1987) 1.15
The treatment of the painful hip in cerebral palsy by total hip replacement or hip arthrodesis. J Bone Joint Surg Am (1986) 1.14
Pathogenicity in mice of herpes simplex virus type 2 mutants unable to express glycoprotein C. J Virol (1986) 1.14
Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A (1996) 1.12